Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2016

Filing Date
Filed February 28, 2017
Period End
December 31, 2016
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’20Mar ’20
  2. Material agreement8-K · Mar ’22Mar ’22
  3. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 28, 2017. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (MEDP) reported Successor full-year 2016 net service revenue of $370.6 milliona, up $50.5 million or 15.8% from $320.1 million in 2015, and total revenue of $421.6 million.

Net income was $13.4 millionb, compared with a net loss of $8.7 million in 2015. Income from operations rose to $52.5 million from $20.6 million, helped by lower amortization and the absence of a 2015 goodwill impairment, while direct costs grew 21.3% to $198.5 million on added headcount. The company describes itself as one of the world's leading clinical CROs, focused on full-service Phase I-IV development for small and mid-sized biopharmaceutical companies, which it says make up 64.8% and 23.0% of net service revenue respectively in 2016.

Backlog rose 12.6% to $483.9 millionc at December 31, 2016, and net new business awards were $427.0 million, versus $359.5 million in 2015. The filing states that approximately $265 million to $275 million of backlog is expected to convert to net service revenue in 2017. Backlog is terminable without cause in most cases, and the filing cautions that it may not be a reliable predictor of future results.

The company completed its IPO on August 11, 2016 at $23.00d per share, raising net proceeds of about $173.6 million, which were used to repay $175.0 million of 2014 term loan borrowings. Ownership and leverage are key investor considerations. Cinven owned approximately 56.5% of outstanding shares and founder Dr. August J.

Troendle controls about 25.6% as of December 31, 2016, making the company a controlled company under NASDAQ rules. At year-end, total debt was $165.0 million under a new Senior Secured Term Loan Facility, with a $150.0 million undrawn revolver, and goodwill and intangibles represented 81.4% of total assets.

Key Highlights

  1. Net service revenue of $370.6 million in 2016, up 15.8% from $320.1 million; total revenue of $421.6 million
  2. Net income of $13.4 million (diluted EPS $0.37) versus a net loss of $8.7 million in 2015
  3. Backlog up 12.6% to $483.9 million; net new business awards of $427.0 million; $265-275 million of backlog expected to convert to revenue in 2017
  4. Customer mix: 64.8% small biopharma, 23.0% mid-sized biopharma, 12.2% large pharma; top 10 customers were 37.0% of net service revenue
  5. IPO on NASDAQ (MEDP) on August 11, 2016 at $23.00 per share, raising about $173.6 million in net proceeds used to repay term loan debt
  6. Total debt of $165.0 million at year-end 2016 after refinancing into a Senior Secured Credit Facility, with $150.0 million available under the revolver
  7. Cinven (about 56.5%) and Dr. Troendle (about 25.6%) control the company, which qualifies as a controlled company under NASDAQ rules

Financial Statements

FY2016 against FY2015

Line itemFY2016FY2015Change
Revenue$421.58M$359.06M+17.4%
SG&A Expenses$61.51M$57.00M+7.9%
Operating Expenses$369.09M$338.50M+9.0%
Operating Income$52.49M$20.56M+155.3%
Net Income$13.43M-$8.67M+254.8%
EPS (Basic)$0.38$-0.28+235.7%
EPS (Diluted)$0.37$-0.28+232.1%
Shares Outstanding (Basic)35.69M31.35M+13.9%
Shares Outstanding (Diluted)36.33M31.35M+15.9%

Frequently Asked Questions

  1. How did Medpace's revenue and profitability change in 2016?

    Net service revenue rose 15.8% to $370.6 million, and total revenue (including reimbursed out-of-pocket revenue) reached $421.6 million, up 17.4%. Income from operations increased to $52.5 million from $20.6 million, largely because of lower amortization and no goodwill impairment in 2016 (the 2015 impairment was $9.3 million). Net income was $13.4 million, compared with a net loss of $8.7 million in 2015.

  2. How much business does Medpace have in the pipeline?

    Backlog was $483.9 million at December 31, 2016, up $54.2 million or 12.6% from $429.7 million a year earlier. Net new business awards were $427.0 million in 2016. The filing expects approximately $265 million to $275 million of backlog to convert to net service revenue in 2017. The filing notes that backlog is generally terminable without cause and may not reliably predict future results.

  3. Who controls Medpace and what does that mean for public shareholders?

    As of December 31, 2016, Cinven owned about 56.5% of outstanding common stock and Dr. August J. Troendle, the CEO and founder, controlled about 25.6% through direct and beneficial ownership. Under a Voting Agreement, the two parties together can control director elections and other shareholder-approved matters. The company is a controlled company under NASDAQ rules and relies on related exemptions from certain governance requirements, and its interests may differ from those of other shareholders.

  4. How is Medpace's debt structured?

    At December 31, 2016, the company had $165.0 million outstanding under a Senior Secured Term Loan Facility maturing in December 2021, with a first amortization payment due March 31, 2017. A $150.0 million Senior Secured Revolving Credit Facility was undrawn, apart from $0.1 million of letters of credit. Borrowings bear variable interest, and the company reports compliance with its financial covenants. The proceeds from the 2016 credit agreement were used to repay the 2014 Senior Secured Credit Facilities.

  5. What does the filing say about risks tied to goodwill and intangible assets?

    Goodwill of $661.0 million and intangible assets of $136.1 million represented 81.4% of total assets at December 31, 2016. The company tests goodwill annually and found no impairment in its fourth-quarter 2016 assessment. The filing notes that a downturn in the business or industry could lead to future impairment charges, as happened with the $9.3 million Clinics reporting unit impairment in 2015.